Abstract
Background/objectives
To prospectively evaluate changes in peripapillary retinal nerve fibre layer (pRNFL), in all macular layers and in choroidal thickness (CT) in a cohort of systemic lupus erythematosus (SLE) patients without ophthalmologic manifestations. To associate those changes with ophthalmic characteristics, disease activity state, medication and systemic comorbidities.
Subjects/methods
Prospective cohort study of 68 previously diagnosed SLE patients. In two study visits (V1 and V2) at least 12 months apart, patients underwent a complete ophthalmologic examination including spectral domain-optical coherence tomography (SD-OCT) and an autoimmune disease specialist assessment. Automatic retinal segmentation was performed. pRNFL was determined globally and in the six peripapillary sectors and each macular layer thickness was determined in the nine early treatment diabetic retinopathy study (ETDRS) subfields. CT was manually measured at 13 locations in the posterior pole. Only one eye per patient was randomly selected for inclusion. Generalised linear mixed effects models were employed.
Results
Sixty-five patients completed the study. The median follow-up time was twelve months. At V2, pRNFL was significantly thinner globally (p = 0.006) and in the temporal inferior sector (p = 0.017). Patients under chronic medication with anticoagulants or antihypertensives had significantly thinner pRNFL in some locations. No significant changes were observed in macular layers or choroidal thickness between study visits.
Conclusions
SLE patients presented early SD-OCT signs of neurodegeneration, evidenced by a progressive reduction in pRNFL thickness. Regardless of study visit, baseline chronic medication with anticoagulants or antihypertensives was associated with lower pRNFL thickness, accounting for a deleterious effect of cardiovascular risk factors.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Sankowski R, Mader S, Valdés-Ferrer SI. Systemic inflammation and the brain: Novel roles of genetic, molecular, and environmental cues as drivers of neurodegeneration. Front Cell Neurosci. 2015;9:28.
Liang MH, Corzillius M, Bae SC, Lew RA, Fortin PR, Gordon C, et al. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599–608.
Mak A, Cheung MWL, Chiew HJ, Liu Y, Roger Chun-man HO. Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum. 2012;41:830–9.
Hanly JG, Urowitz MB, Jackson D, Bae SC, Gordon C, Wallace DJ, et al. SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011;70:961–7.
Sarbu N, Toledano P, Calvo A, Roura E, Sarbu MI, Espinosa G, et al. Advanced MRI techniques: biomarkers in neuropsychiatric lupus. Lupus. 2017;26:510–6. https://doi.org/10.1177/0961203316674820.
Sarbu N, Alobeidi F, Toledano P, Espinosa G, Giles I, Rahman A, et al. Brain abnormalities in newly diagnosed neuropsychiatric lupus: systematic MRI approach and correlation with clinical and laboratory data in a large multicenter cohort. Autoimmun Rev. 2015;14:153–9.
Zhu CM, Ma Y, Xie L, Huang JZ, Sun ZB, Duan SX, et al. Spatial working memory impairment in patients with non-neuropsychiatric systemic lupus erythematosus: a blood-oxygen-level dependent functional magnetic resonance imaging study. J Rheumatol. 2017;44:201–8.
Ramage AE, Fox PT, Brey RL, Narayana S, Cykowski MD, Naqibuddin M, et al. Neuroimaging evidence of white matter inflammation in newly diagnosed systemic lupus erythematosus. Arthritis Rheum. 2011;63:3048–57.
Monastero R, Bettini P, Del Zotto E, Cottini E, Tincani A, Balestrieri G, et al. Prevalence and pattern of cognitive impairment in systemic lupus erythematosus patients with and without overt neuropsychiatric manifestations. J Neurol Sci. 2001;184:33–9.
Gendelman O, Tiosano S, Shoenfeld Y, Comaneshter D, Amital H, Cohen AD, et al. High proportions of dementia among SLE patients: a big data analysis. Int J Geriatr Psychiatry. 2018;33:531–6.
Ctori I, Huntjens B. Repeatability of foveal measurements using spectralis optical coherence tomography segmentation software. PLoS ONE. 2015;10:e0129005.
Cunha JP, Proença R, Dias-Santos A, Almeida R, Águas H, Alves M, et al. OCT in Alzheimer’s disease: thinning of the RNFL and superior hemiretina. Graefes Arch Clin Exp Ophthalmol. 2017;255:1827–35.
Inzelberg R, Ramirez JA, Nisipeanu P, Ophir A. Retinal nerve fiber layer thinning in Parkinson disease. Vis Res. 2004;44:2793–7.
Toledo J, Sepulcre J, Salinas-Alaman A, García-Layana A, Murie-Fernandez M, Bejarano B, et al. Retinal nerve fiber layer atrophy is associated with physical and cognitive disability in multiple sclerosis. Mult Scler. 2008;14:906–12.
Dias-Santos A, Tavares Ferreira J, Pinheiro S, Cunha JP, Alves M, Papoila AL, et al. Neurodegeneration in systemic lupus erythematosus: Layer by layer retinal study using optical coherence tomography. Int J Retina Vitreous. 2020;6:15. https://doi.org/10.1186/s40942-020-00219-y. Accessed 1 May 2020.
Liu GY, Utset TO, Bernard JT. Retinal nerve fiber layer and macular thinning in systemic lupus erythematosus: an optical coherence tomography study comparing SLE and neuropsychiatric SLE. Lupus. 2015;24:1169–76.
Shulman S, Shorer R, Wollman J, Dotan G, Paran D. Retinal nerve fiber layer thickness and neuropsychiatric manifestations in systemic lupus erythematosus. Lupus. 2017;26:1420–5.
Tavares Ferreira J, Alves M, Dias-Santos A, Costa L, Santos BO, Cunha JP, et al. Retinal neurodegeneration in diabetic patients without diabetic retinopathy. Investig Ophthalmol Vis Sci. 2016;57:6455–60.
Karaca C, Karaca Z. Beyond hyperglycemia, evidence for retinal neurodegeneration in metabolic syndrome. Investig Ophthalmol Vis Sci. 2018;59:1360–7.
Przedborski S, Vila M, Jackson-Lewis V. Neurodegeneration: what is it and where are we? J Clin Investig. 2003;111:3–10.
Carlomagno S, Migliaresi S, Ambrosone L, Sannino M, Sanges G, Di, et al. Cognitive impairment in systemic lupus erythematosus: a follow-up study. J Neurol. 2000;247:273–9.
Hanly JG, Fisk JD, Sherwood G, Eastwood B. Clinical course of cognitive dysfunction in systemic lupus erythematosus. J Rheumatol. 1994;21:1825–31.
Kozora E, Filley CM, Erkan D, Uluğ AM, Vo A, Ramon G, et al. Longitudinal evaluation of diffusion tensor imaging and cognition in systemic lupus erythematosus. Lupus. 2018;27:1810–8.
Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40:1725.
Ryan TP. Sample size determination and power. New Jersey: John Wiley & Sons; 2013.
Marmor MF, Kellner U, Lai TYY, Melles RB, Mieler WF, Lum F. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016;123:1386–94.
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, Austin A, et al. Derivation of the sledai. A disease activity index for lupus patients. Arthritis Rheum. 1992;35:630–40. http://www.ncbi.nlm.nih.gov/pubmed/1599520.
Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Early treatment diabetic retinopathy study research group. Arch Ophthalmol. 1985;103:1796–806.
Spaide RF, Koizumi H, Pozonni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol. 2008;146:496–500.
Demir S, Artim-Esen B, Şahinkaya Y, Pehlivan, Alpay-Kanltez N, Omma A, et al. Metabolic syndrome is not only a risk factor for cardiovascular diseases in systemic lupus erythematosus but is also associated with cumulative organ damage: a cross-sectional analysis of 311 patients. Lupus. 2016;25:177–84.
Mok CC, Tse SM, Chan KL, Ho LY. Effect of the metabolic syndrome on organ damage and mortality in patients with systemic lupus erythematosus: a longitudinal analysis. Clin Exp Rheumatol. 2018;36:389–95.
Conigliaro P, Triggianese P, Draghessi G, Canofari C, Aloe G, Chimenti MS, et al. Evidence for the detection of subclinical retinal involvement in systemic lupus erythematosus and sjögren syndrome: a potential association with therapies. Int Arch Allergy Immunol. 2018;177:45–56.
Martín-Iglesias D, Artaraz J, Fonollosa A, Ugarte A, Arteagabeitia A, Ruiz-Irastorza G. Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosus. Lupus. 2019;28:555–9.
Esmaeelpour M, Považay B, Hermann B, Hofer B, Kajic V, Kapoor K, et al. Three-dimensional 1060-nm OCT: Choroidal thickness maps in normal subjects and improved posterior segment visualization in cataract patients. Investig Ophthalmol Vis Sci. 2010;51:5260–6.
Ikuno Y, Kawaguchi K, Nouchi T, Yasuno Y. Choroidal thickness in healthy Japanese subjects. Investig Ophthalmol Vis Sci. 2010;51:2173–6.
Baglio V, Gharbiya M, Balacco-Gabrieli C, Mascaro T, Gangemi C, di Franco M, et al. Choroidopathy in patients with systemic lupus erythematosus with or without nephropathy. J Nephrol. 2011;24:522–9.
Trysberg E, Höglund K, Svenungsson E, Blennow K, Tarkowski A. Decreased levels of soluble amyloid beta-protein precursor and beta-amyloid protein in cerebrospinal fluid of patients with systemic lupus erythematosus. Arthritis Res Ther. 2004;6:R129–36.
Trysberg E, Nylen K, Rosengren LE, Tarkowski A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum. 2003;48:2881–7.
Wen J, Doerner J, Weidenheim K, Xia Y, Stock A, Michaelson JS, et al. TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice. J Autoimmun. 2015;60:40–50.
Lu XY, Chen XX, Huang LD, Zhu CQ, Gu YY, Ye S. Anti-alpha-internexin autoantibody from neuropsychiatric lupus induce cognitive damage via inhibiting axonal elongation and promote neuron apoptosis. PLoS One. 2010;5:e11124.
Çetinkaya E, Duman R, Duman R, Sabaner MC. Repeatability and reproducibility of automatic segmentation of retinal layers in healthy subjects using Spectralis optical coherence tomography. Arq Bras Oftalmol. 2017;80:378–81.
Shao L, Xu L, Chen CX, Yang LH, Du KF, Wang S, et al. Reproducibility of subfoveal choroidal thickness measurements with enhanced depth imaging by spectral-domain optical coherence tomography. Investig Ophthalmol Vis Sci. 2013;54:230–3.
Funding
A grant for this study was given by José de Mello Saúde—Hospital CUF Descobertas.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Dias-Santos, A., Tavares Ferreira, J., Pinheiro, S. et al. Retinal and choroidal thickness changes in systemic lupus erythematosus patients: a longitudinal study. Eye 35, 2771–2780 (2021). https://doi.org/10.1038/s41433-020-01292-1
Received:
Revised:
Accepted:
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41433-020-01292-1
This article is cited by
-
Retinal sublayer analysis in juvenile systemic lupus erythematosus without lupus retinopathy
Clinical Rheumatology (2024)
-
Choroidal involvement in systemic vasculitis: a systematic review
Journal of Ophthalmic Inflammation and Infection (2022)
